Index
1 Market Overview
1.1 Product Overview and Scope of Peripherally Acting Anti-Obesity Drug
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Peripherally Acting Anti-Obesity Drug Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Prescription Drugs
1.3.3 Non-prescription Drugs
1.4 Market Analysis by Application
1.4.1 Overview: Global Peripherally Acting Anti-Obesity Drug Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospital Pharmacies
1.4.3 Retail Pharmacies
1.4.4 Online Pharmacies
1.5 Global Peripherally Acting Anti-Obesity Drug Market Size & Forecast
1.5.1 Global Peripherally Acting Anti-Obesity Drug Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Peripherally Acting Anti-Obesity Drug Sales Quantity (2018-2029)
1.5.3 Global Peripherally Acting Anti-Obesity Drug Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Novo Nordisk A/S
2.1.1 Novo Nordisk A/S Details
2.1.2 Novo Nordisk A/S Major Business
2.1.3 Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Product and Services
2.1.4 Novo Nordisk A/S Peripherally Acting Anti-Obesity Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Novo Nordisk A/S Recent Developments/Updates
2.2 Pfizer Inc.
2.2.1 Pfizer Inc. Details
2.2.2 Pfizer Inc. Major Business
2.2.3 Pfizer Inc. Peripherally Acting Anti-Obesity Drug Product and Services
2.2.4 Pfizer Inc. Peripherally Acting Anti-Obesity Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Pfizer Inc. Recent Developments/Updates
2.3 Boehringer Ingelheim International GmbH
2.3.1 Boehringer Ingelheim International GmbH Details
2.3.2 Boehringer Ingelheim International GmbH Major Business
2.3.3 Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Product and Services
2.3.4 Boehringer Ingelheim International GmbH Peripherally Acting Anti-Obesity Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Boehringer Ingelheim International GmbH Recent Developments/Updates
2.4 KVK Tech Inc.
2.4.1 KVK Tech Inc. Details
2.4.2 KVK Tech Inc. Major Business
2.4.3 KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Product and Services
2.4.4 KVK Tech Inc. Peripherally Acting Anti-Obesity Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 KVK Tech Inc. Recent Developments/Updates
2.5 Gelesis Holdings
2.5.1 Gelesis Holdings Details
2.5.2 Gelesis Holdings Major Business
2.5.3 Gelesis Holdings Peripherally Acting Anti-Obesity Drug Product and Services
2.5.4 Gelesis Holdings Peripherally Acting Anti-Obesity Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Gelesis Holdings Recent Developments/Updates
2.6 Vivus LLC.
2.6.1 Vivus LLC. Details
2.6.2 Vivus LLC. Major Business
2.6.3 Vivus LLC. Peripherally Acting Anti-Obesity Drug Product and Services
2.6.4 Vivus LLC. Peripherally Acting Anti-Obesity Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Vivus LLC. Recent Developments/Updates
2.7 Currax Pharmaceuticals LLC
2.7.1 Currax Pharmaceuticals LLC Details
2.7.2 Currax Pharmaceuticals LLC Major Business
2.7.3 Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Product and Services
2.7.4 Currax Pharmaceuticals LLC Peripherally Acting Anti-Obesity Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Currax Pharmaceuticals LLC Recent Developments/Updates
2.8 GlaxoSmithKline plc
2.8.1 GlaxoSmithKline plc Details
2.8.2 GlaxoSmithKline plc Major Business
2.8.3 GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Product and Services
2.8.4 GlaxoSmithKline plc Peripherally Acting Anti-Obesity Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 GlaxoSmithKline plc Recent Developments/Updates
2.9 CHEPLAPHARM Arzneimittel GmbH
2.9.1 CHEPLAPHARM Arzneimittel GmbH Details
2.9.2 CHEPLAPHARM Arzneimittel GmbH Major Business
2.9.3 CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Product and Services
2.9.4 CHEPLAPHARM Arzneimittel GmbH Peripherally Acting Anti-Obesity Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 CHEPLAPHARM Arzneimittel GmbH Recent Developments/Updates
2.10 Rhythm Pharmaceuticals
2.10.1 Rhythm Pharmaceuticals Details
2.10.2 Rhythm Pharmaceuticals Major Business
2.10.3 Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Product and Services
2.10.4 Rhythm Pharmaceuticals Peripherally Acting Anti-Obesity Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Rhythm Pharmaceuticals Recent Developments/Updates
3 Competitive Environment: Peripherally Acting Anti-Obesity Drug by Manufacturer
3.1 Global Peripherally Acting Anti-Obesity Drug Sales Quantity by Manufacturer (2018-2023)
3.2 Global Peripherally Acting Anti-Obesity Drug Revenue by Manufacturer (2018-2023)
3.3 Global Peripherally Acting Anti-Obesity Drug Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Peripherally Acting Anti-Obesity Drug by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Peripherally Acting Anti-Obesity Drug Manufacturer Market Share in 2022
3.4.2 Top 6 Peripherally Acting Anti-Obesity Drug Manufacturer Market Share in 2022
3.5 Peripherally Acting Anti-Obesity Drug Market: Overall Company Footprint Analysis
3.5.1 Peripherally Acting Anti-Obesity Drug Market: Region Footprint
3.5.2 Peripherally Acting Anti-Obesity Drug Market: Company Product Type Footprint
3.5.3 Peripherally Acting Anti-Obesity Drug Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Peripherally Acting Anti-Obesity Drug Market Size by Region
4.1.1 Global Peripherally Acting Anti-Obesity Drug Sales Quantity by Region (2018-2029)
4.1.2 Global Peripherally Acting Anti-Obesity Drug Consumption Value by Region (2018-2029)
4.1.3 Global Peripherally Acting Anti-Obesity Drug Average Price by Region (2018-2029)
4.2 North America Peripherally Acting Anti-Obesity Drug Consumption Value (2018-2029)
4.3 Europe Peripherally Acting Anti-Obesity Drug Consumption Value (2018-2029)
4.4 Asia-Pacific Peripherally Acting Anti-Obesity Drug Consumption Value (2018-2029)
4.5 South America Peripherally Acting Anti-Obesity Drug Consumption Value (2018-2029)
4.6 Middle East and Africa Peripherally Acting Anti-Obesity Drug Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Peripherally Acting Anti-Obesity Drug Sales Quantity by Type (2018-2029)
5.2 Global Peripherally Acting Anti-Obesity Drug Consumption Value by Type (2018-2029)
5.3 Global Peripherally Acting Anti-Obesity Drug Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Peripherally Acting Anti-Obesity Drug Sales Quantity by Application (2018-2029)
6.2 Global Peripherally Acting Anti-Obesity Drug Consumption Value by Application (2018-2029)
6.3 Global Peripherally Acting Anti-Obesity Drug Average Price by Application (2018-2029)
7 North America
7.1 North America Peripherally Acting Anti-Obesity Drug Sales Quantity by Type (2018-2029)
7.2 North America Peripherally Acting Anti-Obesity Drug Sales Quantity by Application (2018-2029)
7.3 North America Peripherally Acting Anti-Obesity Drug Market Size by Country
7.3.1 North America Peripherally Acting Anti-Obesity Drug Sales Quantity by Country (2018-2029)
7.3.2 North America Peripherally Acting Anti-Obesity Drug Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Peripherally Acting Anti-Obesity Drug Sales Quantity by Type (2018-2029)
8.2 Europe Peripherally Acting Anti-Obesity Drug Sales Quantity by Application (2018-2029)
8.3 Europe Peripherally Acting Anti-Obesity Drug Market Size by Country
8.3.1 Europe Peripherally Acting Anti-Obesity Drug Sales Quantity by Country (2018-2029)
8.3.2 Europe Peripherally Acting Anti-Obesity Drug Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Peripherally Acting Anti-Obesity Drug Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Peripherally Acting Anti-Obesity Drug Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Peripherally Acting Anti-Obesity Drug Market Size by Region
9.3.1 Asia-Pacific Peripherally Acting Anti-Obesity Drug Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Peripherally Acting Anti-Obesity Drug Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Peripherally Acting Anti-Obesity Drug Sales Quantity by Type (2018-2029)
10.2 South America Peripherally Acting Anti-Obesity Drug Sales Quantity by Application (2018-2029)
10.3 South America Peripherally Acting Anti-Obesity Drug Market Size by Country
10.3.1 South America Peripherally Acting Anti-Obesity Drug Sales Quantity by Country (2018-2029)
10.3.2 South America Peripherally Acting Anti-Obesity Drug Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Peripherally Acting Anti-Obesity Drug Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Peripherally Acting Anti-Obesity Drug Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Peripherally Acting Anti-Obesity Drug Market Size by Country
11.3.1 Middle East & Africa Peripherally Acting Anti-Obesity Drug Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Peripherally Acting Anti-Obesity Drug Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Peripherally Acting Anti-Obesity Drug Market Drivers
12.2 Peripherally Acting Anti-Obesity Drug Market Restraints
12.3 Peripherally Acting Anti-Obesity Drug Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Peripherally Acting Anti-Obesity Drug and Key Manufacturers
13.2 Manufacturing Costs Percentage of Peripherally Acting Anti-Obesity Drug
13.3 Peripherally Acting Anti-Obesity Drug Production Process
13.4 Peripherally Acting Anti-Obesity Drug Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Peripherally Acting Anti-Obesity Drug Typical Distributors
14.3 Peripherally Acting Anti-Obesity Drug Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer